European community-based intervention project will use Monsenso’s platform to prevent mental illness

European community-based intervention project will use Monsenso’s platform to prevent mental illness

Together with a European consortium of partners, Monsenso has received a grant letter on a new community-based intervention project that includes development and trial of a digital health intervention delivered on Monsenso’s platform to prevent mental illness among vulnerable groups.

Global trends such as war, economic crisis, climate changes, migration, pandemics and ageing population place increasing stress and pressure on European societies. To be able to adapt to fast-changing situations, scalable intervention programmes targeted at building resilience and enhancing self-help competency to prevent mental illness are needed.

Upon receiving this grant letter, Monsenso is now entering into grant agreement negotiations with a consortium of leading researchers in clinical psychology, internet-based therapy, AI and community mental health providers across Europe. The aim of the project is to develop and trial an AI-enabled personalised self-care program based on Monsenso’s platform to help prevent mental illness for high-risk groups. The five-year project is anticipated to start in Q2-2023 and is expected to contribute with DKK 5.7 mio to Monsenso.

“This is the second AI-enabled personalised therapy project that we plan to start in the coming year, and it comes after finalising another European research project this year, where results showed significant effect of delivering digital cognitive behavioral therapy for prevention of mental illness. We will build on the evidence and experience of previous projects and further develop our platform to provide personalised, AI-driven digital programs for people at risk of developing mental illness, so that they can get easy and timely access to evidence-based support”, says Thomas Lethenborg, CEO of Monsenso.

Further information on the project including consortium members, funding program and population groups targeted will be communicated upon signature of a grant agreement, which is expected in Q1 of 2023.
——————————————————————————————————————————-
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endevaours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com.

Monsenso to participate in AI-enabled personalised mental health therapy project

Monsenso to participate in AI-enabled personalised mental health therapy project

Monsenso and a consortium of partners have received a grant letter from a funding entity to develop and trial a new, AI-enabled personalised therapy concept for people with mental disorders.

Currently, digital mental health interventions are largely developed as a one-size-fits-all approach, where patients get a fixed 6-12 week intervention and where drop-out rates are relatively high.

With the grant letter received, Monsenso is entering grant agreement negotiations with a consortium of leading researchers in clinical psychology, internet-based therapy, health economics and AI to develop and trial a new AI-enabled personalised care concept based on Monsenso’s platform. The four-year project is anticipated to start in Q2-2023 and is expected to contribute with DKK 3.9 mio to Monsenso.

“With this project, we will further develop our platform’s ability to deliver personalised digital treatment programs and to ensure optimal adherence to treatment. By leveraging patients’ own data and artificial intelligence, the aim is to be able to give more engaging and personalised care based on patients’ actual state, so that patients are offered the right treatment at the right time in a scalable way”, says Thomas Lethenborg, CEO of Monsenso.

Full disclosure of the project details including consortium members, funding program, and disorder area will be possible upon signature of the grant agreement, which is expected in Q1 of 2023.
——————————————————————————————————————————-
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endevaours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com.

Healthier together – The EU Non-Communicable Diseases Initiative

Healthier together – The EU Non-Communicable Diseases Initiative

Did you know that every year, 41 million people die from non-communicable diseases (71% of all deaths worldwide) and that over 15 million people out of those are only aged 30-69 [1]?

Non-communicable diseases (NCDs) are defined as chronic health conditions that have “genetic, lifestyle, or environmental causes rather than viral or bacterial” ones [2]. NCDs are not contagious, but they do result in long-term health issues and often require long-term treatment and care [2]. Apart from diseases such as cancer or diabetes, mental disorders also fall into the category of non-communicable diseases [1]. 

In a previous blog post, we explored approaches taken to improve mental health in Denmark. But what are we actually doing on an EU level to ease the burden of mental illness on our international societies?

The  EU Non-Communicable Diseases Initiative
In order to fight non-communicable diseases and support the people suffering from them, the European Commission has launched the Healthier together – EU Non-Communicable Diseases Initiative (EU NCD Initiative), aimed at covering the period from 2022 to 2027. The main objective of this initiative is “to support EU countries in identifying and implementing effective policies and actions to reduce the burden of major non-communicable diseases (NCDs) and improve citizens’ health and well-being.” [3].

One of the five strands covered by the initiative is mental health and neurological disorders.
The EU NCD Initiative aims at mental health and well-being promotion, improved prevention and treatment of mental disorders, and better support for individuals suffering from mental health problems. In order to accomplish this, a need for setting up improved “supportive structures, mechanisms and processes for integrated policies and actions to support mental health” has been defined [3].

Collaborative action on mental health and neurological disorders
The European Commission has suggested several “work packages” on mental health and neurological disorders, with the goal to reduce the burden of mental illness on our international society. Possible priority areas defined include:

  • Adopting a mental health-in-all-policies approach: Overall creation of favourable conditions addressing environmental and social determinants for better mental health 
  • Focusing on mental health promotion and mental illness prevention, e.g. by supporting “the development of social and emotional skills in childhood” [3] and by preventing burnout and stress at the workplace
  • Improving the provision of access to high-quality mental health services, e.g. by increasing the capacity in order to meet the growing need for mental health support
  • Tackling stigma against mental health conditions and enhancing the social inclusion of individuals suffering from poor mental health

Digitalization needs to become a priority
According to Dr Hans Henri P. Kluge, WHO Regional Director for Europe, “personnel shortages [and] insufficient recruitment and retention […] are blighting health systems” [4].

While the need to hire more trained professionals is undoubtedly critical to improve mental health services, this may also be an opportunity for scalable technologies to improve the reach of the current workforce to serve the needs of patients waiting to receive care.

Surprisingly, when being asked to indicate overall priority areas across the different strands covered by the NCD initiative, only two EU countries (specify which) endorsed “digital tools to support health promotion, disease prevention and management” as a priority area [3].

In contrast, a large study by Elsevier Health (2022) shows that 77% of international clinicians expect tech companies to become “key stakeholders in managing healthcare systems in 10 years”, and that the majority of clinicians (70%) believe an increased use of digital technologies will transform healthcare positively [5].

The use of digital technology offers the potential to address challenges in European mental health services. In particular, the use of digital platforms for remote patient monitoring and health assessment could improve access and speed to care, and real-time patient analytics could enable personalised treatment and improved quality of care [5]. 

In summary, the EU Non-Communicable Diseases Initiative has ambitious goals to provide better mental health services to more people. However, with the majority of EU countries not endorsing “digital tools to support health promotion, disease prevention and management” [3] as a priority area, raising awareness about the potential of digital health is highly important if these goals are to be achieved.
——————————————————————————————————————————-
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endevaours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com.

References:
[1] World Health Organization (2021). Noncommunicable diseases. 
https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases

[2] WebMD (n.d.). What Is Non-Communicable Disease?
https://www.webmd.com/a-to-z-guides/what-is-non-communicable-disease

[3] European Commission (2022). Healthier Together – EU non-Communicable Disease Initiative.
https://health.ec.europa.eu/non-communicable-diseases/healthier-together-eu-non-communicable-diseases-initiative_en

[4] World Health Organization (2022). Ticking timebomb: Without immediate action, health and care workforce gaps in the European Region could spell disaster.
https://www.who.int/europe/news/item/14-09-2022-ticking-timebomb–without-immediate-action–health-and-care-workforce-gaps-in-the-european-region-could-spell-disaster

[5] Elsevier Health (2022). Clinician of the Future Report 2022.
https://www.elsevier.com/connect/clinician-of-the-future

Monsenso releases enhanced version of its clinical web portal & refreshed patient app

Monsenso releases enhanced version of its clinical web portal & refreshed patient app

Monsenso releases an enhanced version of its clinical web portal and a refreshed patient app. The product enhancements entail an improved and even more intuitive user interface of the solution’s patient app and clinical web portal in order to enhance remote patient monitoring and treatment support for clinicians, as well as the communication and collaboration between clinician and patient.

Among others, the enhancements allow clinicians to recommend treatment content to the patients individually to support personalised treatment. Clinicians can now recommend their patients to do specific exercises, visit the library with psychoeducational content or answer a specific clinical questionnaire. Once the clinician has made a recommendation via the clinical web portal, patients are notified and it is immediately emphasised in the patient’s app. This allows clinicians to provide more personalised treatment and also helps engage and empower patients in taking care of their own mental health.

The product enhancements result from an extensive, user-centered design process involving patients and clinicians in both design and testing phases to ensure the enhancements meet the needs of our users.

“We are excited to offer an improved version of our digital health solution to partners, clients, and patients. The feedback we have received during extensive internal and external testing periods has been excellent, and we are looking forward to empowering individuals, their carers, and clinicians even more on the treatment pathway”, says CEO, Thomas Lethenborg.
——————————————————————————————————————————-
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endevaours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com.

Monsenso signs contract with private Danish psychiatric clinic Appia Klinikken in Søborg

Monsenso signs contract with private Danish psychiatric clinic Appia Klinikken in Søborg

Monsenso signs a contract with the private Danish psychiatric clinic Appia Klinikken in Søborg, Zealand. The Monsenso digital health solution will be implemented at the beginning of 2023 and will be used to support patients and clinicians at the clinic.

Appia Klinikken is a Danish specialist psychiatric clinic offering treatment and support to individuals suffering from mental illness. Though the clinic has a focus on child and adolescent mental health, it offers treatment to individuals of all age groups.

The team of psychologists and psychiatrists at Appia Klinikken is led by specialist psychiatrist Mie Bonde, who “is professionally recognized for her holistic approach and for her work with clients with ADHD and/or ASD diagnoses, as well as clients with abuse combined with diagnosis(es)” [1].

The Monsenso solution will be used at Appia Klinikken for two different purposes. Primarily, the Monsenso solution will be used to screen patients while they are waiting for treatment and to monitor them during treatment. Secondly, the Monsenso solution will be used to collect data for effect documentation of a newly established type of treatment called “hypnotherapy” and for use of medication.

Specialist psychiatrist Mie Bonde says: “The Monsenso digital health solution will not only enable us to support patients more actively during treatment, but also to give patients information on how to reduce stress while they are still waiting to receive treatment. Waiting lists are something we cannot avoid entirely, but tools like the Monsenso solution enable us to make them more proactive”.
——————————————————————————————————————————-
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endevaours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com.

References:
[1] Appia Klinikken (n.d.). Appia Klinikken – Vejenes dronning.
https://www.appia-klinikken.dk/